Received: 19 April 2021     | Revised: 25 May 2021 | Accepted: 21 June 2021
DOI: 10.1002/mp.15069


AAPM SCIENTIFIC REPORT




Report of AAPM Task Group 219 on independent
calculation- based dose/MU verification for IMRT

Timothy C. Zhu1 | Sotiris Stathakis2 | Jennifer R. Clark3 | Wenzheng Feng4 |
Dietmar Georg5 | Shannon M. Holmes6 | Stephen F. Kry7 |
Chang- Ming Charlie Ma8 | Moyed Miften9 | Dimitris Mihailidis1 |
Jean M. Moran10 | Niko Papanikolaou2 | Bjorn Poppe11 | Ying Xiao1
1
 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
2
    Department of Radiation Oncology, UTHSCSA, San Antonio, TX, USA
3
    Sun Nuclear Corporation, Melbourne, FL, USA
4
    Department of Radiation Oncology, Columbia University, New York, NY, USA
5
    Department of Radiation Oncology, Medical University Vienna, Vienna, Austria
6
    Standard Imaging, Middleton, WI, USA
7
    IROC, UT MD Anderson Cancer Center, Houston, TX, USA
8
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
9
    Department of Radiation Oncology, University of Colorado Denver, Aurora, CO, USA
10
     Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
11
    Pius Hospital & Carl von Ossietzky University, Oldenburg, Germany



Correspondence                                  Abstract
Timothy C. Zhu, University of
Pennsylvania, Philadelphia, PA, USA.            Independent verification of the dose per monitor unit (MU) to deliver the prescribed
Email: Timothy.Zhu@pennmedicine.
upenn.edu
                                                dose to a patient has been a mainstay of radiation oncology quality assurance
Sotiris Stathakis, Mays Cancer Center
                                                (QA). We discuss the role of secondary dose/MU calculation programs as part
- MD Anderson Cancer Center, San                of a comprehensive QA program. This report provides guidelines on calculation-
Antonio, TX, USA.
Email: Stathakis@uthscsa.edu                    based dose/MU verification for intensity modulated radiation therapy (IMRT) or
                                                volumetric modulated arc therapy (VMAT) provided by various modalities. We
                                                provide a review of various algorithms for “independent/second check” of moni-
                                                tor unit calculations for IMRT/VMAT. The report makes recommendations on the
                                                clinical implementation of secondary dose/MU calculation programs; on commis-
                                                sioning and acceptance of various commercially available secondary dose/MU
                                                calculation programs; on benchmark QA and periodic QA; and on clinically rea-
                                                sonable action levels for agreement of secondary dose/MU calculation programs.


Abbreviations: A(d), Attenuation function as a function of depth d; BEV, Beam's eye view; C/S, Convolution/Superposition; D, Absorbed dose; dmax, Depth of
maximum dose; Dp, Primary dose, that is, dose from charged particles released from the photon's first interaction in the patient; Ds, Scatter dose, that is, dose
from charged particles released from the photon's second or later interactions in the patient; DLG, Dosimetric leaf gap; DTA, Distance-to- agreement; DVH,
Dose–volume histogram; GBBS, Grid- Based Boltzmann Solver; IMRT, Intensity modulated radiation therapy; f, Source-to- detector distance; fMU, Fractional
MU; K, Collision kerma (Kd for direct beam, Kair for kerma in air, Kh for headscatter component); ks, Scatter polyenergetic point- spread kernel; MCI, Modified
Clarkson Integration; MU, Monitor unit; OAR, Off- axis ratio; POAR, Primary off- axis ratio; PDD, Percentage depth dose; ROI, Region of interest; s, Projected
field size at point of interest; SAD, Source-to- axial distance, usually 100 cm; SPD, Source-to- point distance; SSD, Source-to- skin distance; SDD, Source-to-
detector distance; Sc, In- air output ratio; Scp, (In-water) output ratio; SPR, Scatter-to- primary dose ratio; SF, Dose scatter factor, equals 1+SPR; Sp, Phantom
scatter factor; TPS, Treatment planning system; TMR, Tissue- maximum ratio; TPR, Tissue- phantom ratio; x, y, Lateral positions relative to central axis of
radiation source; VMAT, Volumetric arc therapy; z, Distance from the source to the point of interest.

© 2021 American Association of Physicists in Medicine

e808     wileyonlinelibrary.com/journal/mp		
Medical Physics. 2021;00:1–22.                                                                                                                                 |
                                                                                                                              Medical Physics. 2021;48:e808–e829.
                                                                                                                          wileyonlinelibrary.com/journal/mp    1
                                                                                                            REPORT
                                                REPORT OF AAPM TASK GROUP 219 ON INDEPENDENT CALCULATION- BASED     OF AAPM TASK
                                                                                                                DOSE/
                                                               |




                                                                                                                                                          24734209, 2021, 10, Downloaded from https://aapm.onlinelibrary.wiley.com/doi/10.1002/mp.15069, Wiley Online Library on [03/05/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
2 |
AAPM SCIENTIFIC REPORT                                     2                                 MU VERIFICATION FOR e809
                                                                                                                 IMRT



1 | STATE M ENT O F TH E PRO BLE M                          1verification
                                                                  | STATE     M ENT
                                                                          program was O F TH Eused
                                                                                      generally PRO forBLE  M
                                                                                                       the ma-                                          verifica
A N D TG CH A RG ES                                         Ajority
                                                               ND ofTG    CH  A RG ES
                                                                        IMRT/VMAT treatment plans although ap-                                          jority
                                                              proximately 31% of responders did not use dose/MU                                         proxim
An independent check of dose/monitor units has been         An    independent
                                                              verification      softwarecheckfor   of VMAT
                                                                                                       dose/monitor
                                                                                                                  treatment   units   hasat
                                                                                                                                  plans       been
                                                                                                                                                that    verifica
and continue to be an important part of quality assur-      and     continue      to   be    an    important
                                                              time. The most common commercial system reported       part  of   quality     assur-      time. T
ance (QA) for patient treatment plans. AAPM Report          ance
                                                              in the(QA)survey for patient
                                                                                     was RadCalc  treatment         plans. Tyler,
                                                                                                              (Lifeline,       AAPMTX).   ReportThe     in the
Task Group 71 reports on the formalism for calculat-        Task      Group      71
                                                              most common treatment   reports        on    the   formalism
                                                                                                           planning       system  for   calculat-
                                                                                                                                       (TPS)     re-    most c
                                                                                         1
ing monitor units.1 AAPM Task Group 114 reports on          ing    monitor
                                                              ported     in the units.
                                                                                    survey  AAPM wasTask   EclipseGroup       114 reports
                                                                                                                        (Varian,      Palo Alto, on     ported
methods and requirements for verification of data for       methods
                                                              CA). Thisand         requirements
                                                                              is not     to be considered   for verification        of data for
                                                                                                                       as an endorsement                CA). T
                                                                                                                   2
conformal external beam plans.2 The need for mon-           conformal         external       beam
                                                              of these products. The most common passing plans.       The     need     for mon- rate    of the
itor unit verification programs was identified early in     itor
                                                              criteria for dose/MU verification software wasearly
                                                                   unit   verification        programs           was     identified         5% forin    criteria
the adoption of IMRT treatment planning and delivery        the    adoption       of  IMRT       treatment
                                                              IMRT (51%)3 and “None Specified” for VMAT (34%), al-  planning     and     delivery       IMRT (
techniques.3 Several different types of programs were       techniques.
                                                              though 30% Several  of VMATdifferent
                                                                                                 responders    typesused of programs
                                                                                                                               5% as passing  were      though
developed ranging from confirmation of dose at a sin-       developed
                                                              rate. More than 50% of users used a single pointsin-
                                                                              ranging       from      confirmation         of  dose     at  a     for   rate. M
gle point in a simple phantom geometry to calculation       gle
                                                              theirpoint   in a simple
                                                                      calculations         andphantom
                                                                                                 only 6% geometry
                                                                                                                used three-     todimensional
                                                                                                                                    calculation         their ca
of dose at a single point while taking patient anatomy      of   dose
                                                              (3D)       at a single
                                                                      volumetric             point
                                                                                          dose      in while
                                                                                                         the 2012takingsurvey.
                                                                                                                            patientAdditional
                                                                                                                                        anatomy         (3D) v
and geometry into consideration. While these programs       and    geometry        into    consideration.
                                                              measurements (typically the MLC dosimetric leaf gap   While    these    programs          measu
have been in use for some time, guidance was lacking        have
                                                              (DLG)  been     in use for some
                                                                        measurements)               weretime,alsoguidance
                                                                                                                     required was  during lacking
                                                                                                                                              com-      (DLG)
in how to commission such technologies as well as their     inmissioning.
                                                                how to commission               such      technologies
                                                                                 The most common IMRT dose/MU verifi-         as   well  as   their     missio
role as part of an IMRT QA program as was noted in the      role   as  part    of an    IMRT      QA      program
                                                              cation calculation algorithm represented by software      as  was    noted     in the     cation
ASTRO white paper entitled “Safety Considerations for       ASTRO
                                                              in use4,5 at the time was a “factor- based calculation for
                                                                         white     paper      entitled      “Safety     Considerations            al-   in use
IMRT”.4,5                                                   IMRT”.
                                                              gorithm.” Note that the clinical practice has changed,                                    gorithm
   This task group was charged with: (a) Reviewing               This
                                                              with   moretaskwidespread
                                                                                 group wasuse          charged
                                                                                                            of VMAT    with:
                                              
(Content truncated due to size limit. Use line ranges to read in chunks)